Zhitong Financial App News, Shiyao Group (01093.HK) announced that the pluglitine tablets (this product) developed by the Group recently obtained top-line analysis data in a phase III clinical trial of pluglitine, dapagliflozin, and metformin in combination treatment of patients with type 2 diabetes (T2DM).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.